Unibest
← Back to patent-cliff list

CAS 1559-02-0

diethyl cyclopropane-1,1-dicarboxylate

Codes: CABO-017, MONT-015

Application context (from source-drug indications)

Neuroendocrine tumourCabozantinib S-malatePancreatic neuroendocrine tumourCabozantinib S-malateRenal cell carcinomaCabozantinib S-malateHepatocellular carcinomaCabozantinib S-malateThyroid cancerCabozantinib S-malateNeuroendocrine carcinomaCabozantinib S-malateAllergic rhinitisMontelukastAsthmaMontelukastHypersensitivity reactionMontelukastSeasonal allergic rhinitisMontelukastPerennial allergic rhinitisMontelukastExercise-induced asthmaMontelukast

Source drugs (routes using this intermediate)

DrugTierExpiry
Cabozantinib S-malateTier B — Position early2029
MontelukastTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Unibest Nantong cGMP Site4-Hydroxy-6,7-dimethoxyqunioline
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Taizhou GMP-like Site4-((6,7-Dimethoxyquinolin -4-yl)oxy)aniline
Pharmaceutical Intermediates
On requestOn requestOn request
—
Qualified Partner — East China API Works1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.